{"answer":{"query":"trelegy ellipta","resolved_as":"name","packages":4,"applications":["NDA209482"],"identity":{"application_numbers":["NDA209482"],"marketing_categories":["NDA"],"labelers":[{"text":"GLAXOSMITHKLINE","untrusted":true}],"dosage_forms":[{"text":"POWDER","untrusted":true}],"marketing_start":{"earliest":"2017-09-18","latest":"2020-09-09","packages_with_a_start_date":4}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":4,"negotiated_price_ends":null,"rows":[{"ndc":"00173088710","name":{"text":"TRELEGY ELLIPTA 1X30D TRD100/62.5/25MCG PK/CA","untrusted":true},"class":"B","nadac_per_unit":11.15189,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00173088714","name":{"text":"TRELEGY ELLIPTA 1X14D INST100/62.5/25MCG PK/CA","untrusted":true},"class":"B","nadac_per_unit":11.09118,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00173089310","name":{"text":"TRELEGY ELLIPTA 200/62.5/25MCG 1X30D TRADE PACK","untrusted":true},"class":"B","nadac_per_unit":11.15192,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null},{"ndc":"00173089314","name":{"text":"TRELEGY ELLIPTA 200/62.5/25MCG 1X14D INST PACK","untrusted":true},"class":"B","nadac_per_unit":11.20059,"negotiated_per_unit":null,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":175,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA209482","date":"2031-04-11","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"8746242*PED","productNo":"001"},"latest_patent_expiry":"2031-04-11","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":15,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":6,"exclusivities_listed":0,"fact_id":"b99fb867b0fc9b5de4a24667"}],"label_history":{"events_total":9,"non_cmc_events":9,"counts_by_class":{"LABELING":7,"EFFICACY":2},"cmc_events":0,"recent_non_cmc_events":[{"application":"NDA209482","submission_no":18,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-06-02","documents":[{"type":"Letter","date":"2023-06-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/209482Orig1s018ltr.pdf","untrusted":true}},{"type":"Label","date":"2023-06-05","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209482s018lbl.pdf","untrusted":true}}],"fact_id":"36ab862ac6f6b00d860e1b43"},{"application":"NDA209482","submission_no":16,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-12-02","documents":[{"type":"Label","date":"2022-12-05","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209482s016lbl.pdf","untrusted":true}},{"type":"Letter","date":"2022-12-05","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209482Orig1s016ltr.pdf","untrusted":true}}],"fact_id":"ab8410f66f448c58e79625fc"},{"application":"NDA209482","submission_no":13,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-05-11","documents":[{"type":"Letter","date":"2022-05-12","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/209482Orig1s013ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-05-12","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209482s013lbl.pdf","untrusted":true}}],"fact_id":"d42f4066ec86700b51683d48"},{"application":"NDA209482","submission_no":11,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2020-09-09","documents":[{"type":"Letter","date":"2020-09-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209482Orig1s010, s011ltr.pdf","untrusted":true}},{"type":"Label","date":"2020-09-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209482s010s011lbl.pdf","untrusted":true}}],"fact_id":"3e80d94a26db09ca37e9f7fe"},{"application":"NDA209482","submission_no":10,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2020-09-09","documents":[{"type":"Letter","date":"2020-09-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/209482Orig1s010, s011ltr.pdf","untrusted":true}},{"type":"Label","date":"2020-09-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209482s010s011lbl.pdf","untrusted":true}}],"fact_id":"095777d09995fec7ff0dd1dd"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":2,"te_code_counts":{"NOT_PROVIDED":2},"marketing_status_counts":{"Prescription":2},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA209482","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRELEGY ELLIPTA","untrusted":true},"form":{"text":"POWDER;INHALATION","untrusted":true},"strength":{"text":"0.2MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH","untrusted":true}},{"application":"NDA209482","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRELEGY ELLIPTA","untrusted":true},"form":{"text":"POWDER;INHALATION","untrusted":true},"strength":{"text":"0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH","untrusted":true}}]},"recalls":{"recalls_total":2,"counts_by_class":{"Class II":2},"packages_of_these_applications":4,"most_recent":[{"recall_number":"D-0481-2021","classification":"Class II","status":"Terminated","report_date":"2021-06-02","recall_initiated":"2021-03-15","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"CGMP Deviations: Intermittent exposure to temperature excursion during storage.","untrusted":true},"packages_named":4,"fact_id":"fdbdff6fb1690b7ffbfe953a"},{"recall_number":"D-0482-2021","classification":"Class II","status":"Terminated","report_date":"2021-06-02","recall_initiated":"2021-03-15","recalling_firm":{"text":"Cardinal Health Inc.","untrusted":true},"reason":{"text":"CGMP Deviations: Intermittent exposure to temperature excursion during storage.","untrusted":true},"packages_named":4,"fact_id":"d6e405f98122c33e0d713e77"}],"meaning":"FDA classifies the health hazard of a recall, not its effect on supply"},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"GSK Patient Assistance Program","untrusted":true},"type":"manufacturer","url":"https://www.gskpaf.org/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Fluticasone/Umeclidin/Vilanter","untrusted":true},"brand":{"text":"Trelegy Ellipta","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1487802307.7,"claims":1987542,"beneficiaries":419392,"average_spending_per_claim_usd":748.56395872,"fact_id":"06c60ed4a518ee0e9477d17c"},{"year":2021,"gross_spending_usd":2393151302.6,"claims":2964362,"beneficiaries":645157,"average_spending_per_claim_usd":807.30737427,"fact_id":"d2b7650e708f8039d3c3358d"},{"year":2022,"gross_spending_usd":3340110326.4,"claims":3926585,"beneficiaries":834046,"average_spending_per_claim_usd":850.64001578,"fact_id":"e5f2fe436b4b36d8baad9ccf"},{"year":2023,"gross_spending_usd":4455884009.7,"claims":5009961,"beneficiaries":1050583,"average_spending_per_claim_usd":889.40492945,"fact_id":"40006b22c02907df1d3272a5"},{"year":2024,"gross_spending_usd":5294401776.8,"claims":6250872,"beneficiaries":1268914,"average_spending_per_claim_usd":846.98611279,"fact_id":"be0e645923e702e25adc1704"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"medicaid_state_utilization":{"year":2025,"states_with_data":1,"all_states_medicaid_reimbursed_usd":19221.3,"all_states_medicaid_paid_prescriptions":98,"top_states":[{"state":"KY","medicaid_paid_prescriptions":98,"medicaid_reimbursed_usd":19221.3,"total_reimbursed_usd":19221.3,"packages":1,"covers":"fee_for_service_only","fact_id":"507f7a9cf03f162ec5cb8562"}],"unlabelled_state_code_xx":null,"built_from_facts":1,"facts_fee_for_service_only":1,"older_year_facts_not_used":118,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"6c71589dd6d652aac25bc957","field":"ndc.listing","entity":"ndc:00173088710"},{"fact_id":"7ccbe19ce6f73685a9d67a4e","field":"ndc.listing","entity":"ndc:00173088714"},{"fact_id":"783f75f7e386557c71eae0a0","field":"ndc.listing","entity":"ndc:00173089310"},{"fact_id":"b99fb867b0fc9b5de4a24667","field":"drug.generic_entry_earliest","entity":"application:NDA209482"},{"fact_id":"81a0c6f152808eef746bd273","field":"drug.patent","entity":"application:NDA209482"},{"fact_id":"36ab862ac6f6b00d860e1b43","field":"drug.label_event","entity":"application:NDA209482"},{"fact_id":"ab8410f66f448c58e79625fc","field":"drug.label_event","entity":"application:NDA209482"},{"fact_id":"d42f4066ec86700b51683d48","field":"drug.label_event","entity":"application:NDA209482"},{"fact_id":"3e80d94a26db09ca37e9f7fe","field":"drug.label_event","entity":"application:NDA209482"},{"fact_id":"095777d09995fec7ff0dd1dd","field":"drug.label_event","entity":"application:NDA209482"},{"fact_id":"1b5ce7862c887ce5c50887ff","field":"drug.marketing_status","entity":"application:NDA209482"},{"fact_id":"0f20486534cec153022c631f","field":"drug.marketing_status","entity":"application:NDA209482"},{"fact_id":"fdbdff6fb1690b7ffbfe953a","field":"ndc.recall","entity":"ndc:00173089310"},{"fact_id":"d6e405f98122c33e0d713e77","field":"ndc.recall","entity":"ndc:00173089314"},{"fact_id":"06c60ed4a518ee0e9477d17c","field":"drug.partd_spending","entity":"drug:fluticasone-umeclidin-vilanter|trelegy-ellipta"},{"fact_id":"d2b7650e708f8039d3c3358d","field":"drug.partd_spending","entity":"drug:fluticasone-umeclidin-vilanter|trelegy-ellipta"},{"fact_id":"e5f2fe436b4b36d8baad9ccf","field":"drug.partd_spending","entity":"drug:fluticasone-umeclidin-vilanter|trelegy-ellipta"},{"fact_id":"40006b22c02907df1d3272a5","field":"drug.partd_spending","entity":"drug:fluticasone-umeclidin-vilanter|trelegy-ellipta"},{"fact_id":"be0e645923e702e25adc1704","field":"drug.partd_spending","entity":"drug:fluticasone-umeclidin-vilanter|trelegy-ellipta"},{"fact_id":"507f7a9cf03f162ec5cb8562","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00173088714:KY"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"trials","reason":"no ClinicalTrials.gov record set for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"orphan_designation","reason":"no FDA orphan designation for this drug's ingredient is in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}